NASDAQ:PLUR - Nasdaq - US72942G2030 - Common Stock - Currency: USD
NASDAQ:PLUR (2/21/2025, 8:00:01 PM)
4.33
-0.21 (-4.63%)
The current stock price of PLUR is 4.33 USD. In the past month the price increased by 2.61%. In the past year, price decreased by -27.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Pluri Inc is a IL-based company operating in Biotechnology industry. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
PLURI INC
Matam Park Building 5
Haifa IL
Employees: 112
Company Website: https://pluri-biotech.com/
Investor Relations: http://pluri-biotech.com/investors/
Phone: 972747108600
The current stock price of PLUR is 4.33 USD. The price decreased by -4.63% in the last trading session.
The exchange symbol of PLURI INC is PLUR and it is listed on the Nasdaq exchange.
PLUR stock is listed on the Nasdaq exchange.
PLURI INC (PLUR) has a market capitalization of 30.31M USD. This makes PLUR a Nano Cap stock.
PLURI INC (PLUR) currently has 112 employees.
PLURI INC (PLUR) has a support level at 4.32 and a resistance level at 4.43. Check the full technical report for a detailed analysis of PLUR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PLUR does not pay a dividend.
PLURI INC (PLUR) will report earnings on 2025-05-07.
PLURI INC (PLUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.68).
The outstanding short interest for PLURI INC (PLUR) is 0.76% of its float. Check the ownership tab for more information on the PLUR short interest.
ChartMill assigns a technical rating of 1 / 10 to PLUR. When comparing the yearly performance of all stocks, PLUR is a bad performer in the overall market: 84.89% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PLUR. PLUR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months PLUR reported a non-GAAP Earnings per Share(EPS) of -3.68. The EPS increased by 21.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -64.35% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to PLUR. The Buy consensus is the average rating of analysts ratings from 7 analysts.